Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells
✍ Scribed by Hayashi, Hitoshi; Nio, Yoshinori; Kawabata, Kazuya; Araya, Shinichi; Imamura, Masayuki
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 809 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Previous studies have demonstrated the immunomodulatory effects of cisplatin under certain conditions. The present study was designed to clarify whether cisplatin modulates the expression of surface antigens, especially human leukocyte antigen (HLA), on human tumor cell lines and/or augments the susceptibility and binding of tumor cells to cytotoxic effector cells. A human gastric cancer cell line, KATO-3, was employed. The cxpression of HLA and other tumor-associated antigens was analyzed by flow cytometry using FITC-conjugated monoclonal antibodies. The cytotoxicity of effector cells was determined by "Cr release assay. The cxpression of HLA class I antigen, P2-microglobulin. leukocyte functionassociated antigen-1, and AC-8 1 adenocarcinoma-associated antigen on KATO-3 increased after exposure to cisplatin at 10 pg/ml for 3-6 hr; augmentation of HLA class I subtypes -B2 and -B27 was particularly prominent. Furthermore, the susceptibility and binding of KATO-3 to both lymphokine-activated killer cells and KATO-3-specific cytotoxic T lymphocytes significantly increased after cisplatin treatment. Cisplatin may modulate the expression of tumor-associated antigens on some human tumor cells. Tumor regression by cisplatin administration may depend on its direct cytotoxicity as well as on its modulating effects on the expression of tumor-associated antigens, subsequently leading to the activation of the immune surveillance system against the tumor. 0 1996 WiIey-Liss. Inc.